20/20 Biolabs, Inc.
AIDXNasdaq
$0.52
↓ -2.3%Jul 17 close · end-of-day
Price
1Y↓ -97.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.6M
Enterprise Value
-$1.7M
P/E
—
P/S
1.2
P/B
1.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.0M
Net Income (TTM)
-$3.7M
Free Cash Flow (TTM)
—
Gross Margin
29.6%
Operating Margin
-162.9%
Net Margin
-182.8%
ROE
-146.4%
ROIC
—
Debt / Equity
—
Net Cash
$4.2M
Return 1Y
—
Company profile
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. Our principal executive offices are located in Gaithersburg, MD.
- CEO
- Jonathan Cohen
- Sector
- Services
- Industry
- Business Services
- Employees
- 14
- Headquarters
- Maryland
- Website
- 2020biolabs.com
Earnings
AIDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$353,375.00↓ -36.2%
Diluted EPS-$0.28↑ +75.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $1.8M | $2.0M |
| Gross profit | $360,311.00 | $604,541.00 |
| Operating income | -$5.7M | -$3.3M |
| Net income | -$5.6M | -$3.7M |
| Diluted EPS | -$1.16 | -$0.76 |
| Operating cash flow | -$2.6M | -$1.9M |
| Free cash flow | — | — |
| Gross margin | 20.6% | 29.6% |
| Operating margin | -324.0% | -162.9% |
| Net margin | -316.8% | -182.8% |
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | $553,820.00 | $353,375.00 |
| Gross profit | $165,795.00 | $62,884.00 |
| Operating income | -$772,180.00 | -$1.4M |
| Net income | -$764,577.00 | -$2.2M |
| Diluted EPS | -$0.16 | -$0.28 |
| Operating cash flow | -$488,293.00 | -$1.3M |
| Free cash flow | — | — |
| Gross margin | 29.9% | 17.8% |
| Operating margin | -139.4% | -408.4% |
| Net margin | -138.1% | -615.4% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-19 | Rollins John Woodson | C | 13,029 | $0.00 | $0.00 | filing |
| 2026-02-19 | Rollins John Woodson | C | 6,135 | $0.00 | $0.00 | filing |
| 2026-02-19 | Ross Michael A. | C | 31 | $0.00 | $0.00 | filing |
| 2026-02-19 | Compton John G. | C | 7,669 | $0.00 | $0.00 | filing |
| 2026-02-19 | COHEN RICHARD M | C | 7,700 | $0.00 | $0.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.